Pulmonary Hypertension

We have participated in more than 1,200 clinical research trials (130 active trials) and have introduced most of the new techniques in cardiovascular medicine over the past 20 years.

Clinical Trials: Pulmonary Hypertension

Description

Inhaled Iloprost in Pulmonary Hypertension Association with Diastolic Dysfunction (INHALD)

Investigator(s): Engel

Enrolling

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Arterial Hypertension

Investigator(s): Engel

Enrolling

US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice

Investigator(s): Engel

Enrolling

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease

Investigator(s): Engel

Enrolling

An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease

Investigator(s): Engel

Enrolling

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study

Investigator(s): Engel

Enrolling

Investigator(s): Engel

Pending

A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension

Investigator(s): Engel

Follow up only

Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension

Investigator(s): Engel

Follow up only

A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients With Pulmonary Arterial Hypertension Not on Active Treatment

Investigator(s): Engel

Follow up only